Why Biotech ETFs are Rising

Videos
Increasing M&A deals and cutting edge therapies are driving biotech ETFs higher.

IShares Nasdaq Biotechnology ETF: https://www.zacks.com/funds/etf/IBB/profile?cid=CS-YOUTUBE-FT-VID
SPDR S&P Biotech ETF: https://www.zacks.com/funds/etf/XBI/profile?cid=CS-YOUTUBE-FT-VID
ARK Genomic Revolution ETF: https://www.zacks.com/funds/etf/ARKG/profile?cid=CS-YOUTUBE-FT-VID
Virtus LifeSci Biotech Clinical Trials ETF: https://www.zacks.com/funds/etf/BBC/profile?cid=CS-YOUTUBE-FT-VID
ALPS Medical Breakthroughs ETF: https://www.zacks.com/funds/etf/SBIO/profile?cid=CS-YOUTUBE-FT-VID
Merck: https://www.zacks.com/stock/quote/MRK?cid=CS-YOUTUBE-FT-VID
Biogen: https://www.zacks.com/stock/quote/BIIB?cid=CS-YOUTUBE-FT-VID
Sanofi: https://www.zacks.com/stock/quote/SNY?cid=CS-YOUTUBE-FT-VID
ArQule: https://www.zacks.com/stock/quote/ARQL?cid=CS-YOUTUBE-FT-VID
Synthorx: https://www.zacks.com/stock/quote/THOR?cid=CS-YOUTUBE-FT-VID

Follow us on StockTwits: http://stocktwits.com/ZacksResearch
Follow us on Twitter: https://twitter.com/ZacksResearch
Like us on Facebook: https://www.facebook.com/ZacksInvestmentResearch

Articles You May Like

EU shipyards are fixing Russia’s Arctic LNG tankers
European wind stocks tumble after Trump says he will stop new turbine construction
Another volatile UST session leads to losses ahead of $12B calendar
Crypto ETFs have big innovation opportunity in 2025, but demand may be weak
Dollar hits two-year high after robust US data puts brake on rate cut bets